AbTherx Expands Atlas™ Platform with VHH Single-Domain Antibody Technology and Lambda Common Light Chains to Tackle Multispecifics and Undruggable Targets
核心洞察
AbTherx announced the launch of its first human VHH transgenic models, designed to deliver fully human single-domain antibodies for advanced multispecifics, cell therapies, and other complex modalities.
The company expanded its proprietary Binary Fixed Light Chain technology to include lambda light chains, addressing the light chain pairing problem in trispecifics and higher-order multispecifics.
Industry veteran John "Lippy" Lippincott, Ph.D., was appointed Chief Strategy Officer, bringing experience from over 300 antibody discovery programs to the leadership team.
AbTherx, Inc. (搜索), a privately held biotechnology company based in Mountain View, CA, announced on June 10, 2026, a significant expansion of its proprietary Atlas™ Mouse technologies and leadership team, sharpening its discovery focus toward multispecifics and previously undruggable targets. The dual announcement includes the launch of novel human VHH single-domain antibody technology, an expanded common light chain portfolio now encompassing lambda light chains, and the appointment of John "Lippy" Lippincott, Ph.D., as Chief Strategy Officer.
"This dual announcement of our platform expansion and leadership growth marks an exciting moment for the company," said Peter Brams, Co-founder and Chief Scientific Officer of AbTherx. "Dr. Lippincott's complementary experience in building, validating, and implementing several transgenic technologies and his successful track record across over 300 antibody discovery programs firmly establishes our position as leaders in therapeutic antibody discovery for previously intractable targets and higher-order multispecifics."
Leadership Expansion with Proven Expertise
Dr. Lippincott joins an established research leadership team that includes Peter Brams, Ph.D., Dan Rohrer, Ph.D., and Viktoriya Dubrovskaya, Ph.D. This foundational group brings an established synergy, having previously achieved antibody discovery breakthroughs on notoriously challenging drug targets such as GPCRs (搜索) and extracellular enzymes (搜索). In his new role, Dr. Lippincott will contribute to research strategy, biopharma partnerships, and the scaling of AbTherx's rapidly growing platform.
"Joining AbTherx at this pivotal moment is an incredible opportunity," said Lippincott. "The team's early traction with our multispecifics platform and its ability to discover high-quality antibodies against challenging targets like GPCRs (搜索) highlight the strength of these innovative and rapidly expanding technologies. I am excited to work alongside this elite research team, which brings deep specialized hands-on expertise in discovering novel antibody therapeutics in monoclonal and multispecific formats against complex targets such as GPCRs and ion channels (搜索)."
Human VHH Transgenic Models for Next-Generation Modalities
AbTherx is launching its first human VHH transgenic models and advancing a pipeline of next-generation models. Built upon a foundation of wildtype and modified scaffolds, these models are designed to deliver superior developability and broader sequence diversity. By pairing this architecture with AbTherx's proprietary Full Human Diversity and Long CDR3 technologies, the platform will deliver fully human single-domain antibodies in two configurations: standard and long CDR3s. These optimized single-domain antibodies are ultimately intended to serve as building blocks for advanced multispecifics, cell therapies, and other complex modalities.
Expanded Common Light Chain Technologies
The company has expanded its proprietary Binary Fixed Light Chain technology to include lambda light chains, with an additional option for rapidly incorporating alternate light chains modularly. The common light chain approach remains one of the most streamlined and validated strategies for circumventing the light chain pairing problem, a critical challenge especially for trispecifics and other higher-order multispecifics.
As drug discovery increasingly pivots toward complex, multi-targeted therapeutics, particularly trispecifics and higher-order structures, the industry urgently requires platforms that can efficiently generate developable, native IgG-like formats while simultaneously eliminating chain mispairing and safeguarding Freedom to Operate. AbTherx continues to build its technology suite to address these industry needs, anchoring every technology on a foundation of clean, unencumbered FTO to provide a derisked and efficient path from discovery to the clinic.
AbTherx leverages its proprietary Atlas™ Mice transgenic technologies to enable the rapid identification of highly diverse, high-quality, and developable therapeutic candidates for the industry's most challenging drug targets. The company's platform empowers drug developers to reliably deliver innovative medicines to unlock difficult targets with speed and efficiency.